Oxford University Press

SHERPA: Yellow

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Rosenberg
    Rosenberg
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Solit
    Solit
  7. Autio
    Autio
  8. Rathkopf
    Rathkopf
  9. Iyer
    Iyer
  10. Voss
    Voss

Groups

  1. Genitourinary Oncology Service (371)
  2. Solid Tumor Oncology Division (371)
  3. Department of Medicine (369)
  4. GSK Faculty (44)
  5. Epidemiology and Biostatistics (40)
  6. Population Sciences Research Program (33)
  7. Human Oncology and Pathogenesis Program (31)
  8. Department of Pathology and Laboratory Medicine (30)
  9. Survivorship Research (29)
  10. Biostatistics Service (24)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (252)
  2. Journal Article (110)
  3. Editorial (3)
  4. Review (3)
  5. Guidelines (2)
  6. Book Section (1)
Groups
  1. Genitourinary Oncology Service (371)
  2. Solid Tumor Oncology Division (371)
  3. Department of Medicine (369)
  4. GSK Faculty (44)
  5. Epidemiology and Biostatistics (40)
  6. Population Sciences Research Program (33)

More Groups

People
  1. Robert Motzer (100)
  2. Howard Scher (45)
  3. Jonathan Rosenberg (43)
  4. Michael Morris (38)
  5. Dean Bajorin (33)
  6. Dana Rathkopf (27)

More People

Years
  1. 2025 (6)
  2. 2024 (41)
  3. 2023 (27)
  4. 2022 (25)
  5. 2021 (26)
  6. 2020 (22)

More Years

Publications
  1. Annals of Oncology (303)
  2. JNCI: Journal of the National Cancer Institute (35)
  3. JNCI Cancer Spectrum (8)
  4. The Oncologist (7)
  5. Neuro-Oncology (6)
  6. Japanese Journal of Clinical Oncology (3)

More Publications

Results (371)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors
    Journal Article

    Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
    Guidelines

    Westphalen, C. B.; Boscolo Bielo, L.; Aftimos, P.; Beltran, H.; Benary, M.; Chakravarty, D.; Collienne, M.; Dienstmann, R.; El Helali, A.; Gainor, J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors
    Journal Article

    Nykaza, I.; Murciano-Goroff, Y. R.; Desilets, A.; Harada, G.; Postow, M. A.; Callahan, M. K.; Lee, C. H.; Rudin, C. M.; Kelsen, D. P.; Stadler, Z. K.; more...
    The Oncologist (2025)

    Fulltext@MSK | Save
  • Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: Final analysis of the phase III JAVELIN Renal 101 trial
    Journal Article

    Choueiri, T. K.; Penkov, K.; Uemura, H.; Campbell, M. T.; Pal, S.; Kollmannsberger, C.; Lee, J. L.; Venugopal, B.; van den Eertwegh, A. J. M.; Negrier, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Biomarker analyses from the phase III randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N.; Hawley, J. E.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K. D.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
    Meeting Abstract

    Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Powles, T. B.; van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Maroto Rey, J. P.; Vulsteke, C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save